Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes Combined With Bevacizumab in Progressive or Recurrent Glioma
NCT06801730Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Conditions
- glioma
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in glioma. Primary endpoint: Objective Response Rate at 1 year. Started Jan 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Irinotecan liposome + Bevacizumab
Irinotecan liposomes 50mg/m2 Q2W + Bevacizumab 10mg/kg Q2W
03
Who it enrols
Adult patients (18-75) with histologically diagnosed progressive or recurrent glioma who have progressed on first-line therapy and have not received prior irinotecan. Patients must have good organ function and ECOG 0-1.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT06801730.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801730.